Oncotarget

Reviews:

Could ALDH2*2 be the reason for low incidence and mortality of ovarian cancer for East Asia women?

Shaomin Yan and Guang Wu _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:12503-12512. https://doi.org/10.18632/oncotarget.23605

Metrics: PDF 387 views  |   HTML 992 views  |   ?  


Abstract

Shaomin Yan1 and Guang Wu1

1Bioscience and Technology Research Center, Guangxi Academy of Sciences, Nanning, Guangxi, 530007, China

Correspondence to:

Guang Wu, email: hongguanglishibahao@yahoo.com

Keywords: aldehyde dehydrogenase 2; ALDH2*2; East Asian; stem cell; ovarian cancer

Received: July 03, 2017     Accepted: December 16, 2017     Published: December 22, 2017

ABSTRACT

It is curious that East Asian women have a low incidence and mortality of ovarian cancer in various epidemiological studies. Although different explanations were given, they appear unsubstantial. We notice that East Asian population usually are inactive aldehyde dehydrogenase 2 mutation (ALDH2*2) carriers, and ALDH plays an important role in the resistance of ovarian cancer to chemotherapeutics, especially in ovarian cancer stem cells. Therefore, we hypothesize whether ALDH2 mutation is the major reason for low incidence and mortality of ovarian cancer in East Asian women, and use the evidence from literature, transcriptomic data with average 5-year overall survival to confirm our hypothesis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 23605